Dupilumab was previously shown to reduce thymus and activation-regulated chemokine (TARC/CCL17) and total IgE levels in multiple type 2 inflammatory diseases, including atopic dermatitis (AD). Here, we assess the effects of dupilumab treatment on these biomarkers of type 2 inflammation in children aged 6 months –5 years with moderate-to-severe AD. In LIBERTY AD PRE-SCHOOL (NCT03346434 part B), a phase 3, double-blind trial, children aged ≥ 6 months – 5 years with moderate-to-severe AD inadequately controlled with topical therapies were randomized 1:1 to subcutaneous dupilumab (200 mg if baseline weight ≥ 5 – < 15 kg, 300 mg if ≥ 15 – < 30 kg) or placebo every 4 weeks for 16 weeks. All patients received standardized low-potency topical corticosteroids. Serum for biomarker analysis was collected at baseline, Week 4, and Week 16. Baseline median serum TARC and total IgE levels for dupilumab/placebo groups (n = 83/79) were 3,295/3,190 pg/mL and 2,190/3,240 kU/L, respectively. After 16 weeks of treatment, median % change from baseline in dupilumab/placebo was –83.1%/–12.8% for TARC and –71.2%/28.1% for total IgE (both P<0.0001). Similar reductions were observed in dupilumab- vs placebo-treated patients for all tested serum allergen-specific IgEs (peanut, egg white, soybean, Dermatophagoides farinae and Dermatophagoides pteronyssinus). Dupilumab significantly reduced serum TARC and total and allergen-specific IgEs in children aged 6 months – 5 years with moderate-to-severe AD vs placebo-treated controls, reflecting reduction of systemic type 2 inflammation.

ESDR408 - Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to 5 years with moderate-to-severe atopic dermatitis

The scientific meeting of the European Society for Dermatological Research (ESDR) is held yearly, usually in September. With an international attendance of more than 1000 skin scientists from around the globe, the four-day event includes short oral presentations from peer-reviewed abstracts, keynote lectures from international experts, sponsored symposia, satellite programs, educational events as well as an important focus on posters, networking and building collaborations amongst scientists. For more information about this year’s meeting visit our website.